DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
A multidisciplinary, virtual platform showed preliminary feasibility for reducing distress and improving access for patients ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...
A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...
Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
Pro-ocular™ is a novel drop-free therapy poised to revolutionize the treatment of ocular Graft-versus-Host Disease (oGvHD). This key regulatory milestone, achieved following a highly productive ...
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback